Trials / Completed
CompletedNCT03278028
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 8 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
Detailed description
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week. The secondary objectives of this study are to evaluate the clinical effect of A-101 when applied to all treated Warts (Target Warts plus Non-Target Warts) twice a week, duration of response in all treated Warts (Target Warts plus Non-Target Warts), and safety of A-101.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | A-101 Topical Solution | A-101 Topical Solution |
| DRUG | A-101 Vehicle Solution | A-101 Vehicle Solution |
Timeline
- Start date
- 2017-07-13
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2017-09-11
- Last updated
- 2019-04-09
- Results posted
- 2019-03-29
Locations
16 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03278028. Inclusion in this directory is not an endorsement.